Heart-Block Test Could Bring Volcano, St. Jude $2 Billion
This article is for subscribers only.
Volcano Corp.’s test that shows which patients need heart stents could lead to a $2 billion market within a decade as more doctors use it to improve care, Chief Executive Officer Scott Huennekens said.
Volcano, based in San Diego, and St. Jude Medical Inc., based in St. Paul, Minnesota, are the only two companies that sell the technology, known as fractional flow reserve, or FFR. Volcano and St. Jude are both expanding in a “duopoly market,” Huennekens said yesterday during a presentation at the JPMorgan & Chase Co. health-care conference in San Francisco.